Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer
September 28th 2017Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.
Read More
Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC
October 26th 2016Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).
Read More